Vanda Pharmaceuticals Inc.
VNDANASDAQHealthcare● Active
$5.94
$-0.09(-1.49%)
Market Cap$357205238
P/E Ratio—
52W High$9.94
52W Low$4.14
Vanda Pharmaceuticals Inc. (VNDA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VNDA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.82
Est. -$0.53 · -54.7%
Revenue
$0.05B
Est. $0.05B · -5.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
VNDA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$0.60 | — | — | — | $0.06B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.53 | -$0.82 | -54.7% | $0.05B | $0.05B | -5.9% |
| ▲ Q1 FY2026 | Feb 11, 2026 | -$2.18 | -$0.46 | +78.9% | $0.06B | $0.06B | -3.5% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -$0.31 | -$0.38 | -22.6% | $0.06B | $0.06B | -5.1% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$0.34 | -$0.46 | -35.3% | $0.05B | $0.06B | -10.5% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.55 | -$0.50 | +9.1% | $0.05B | $0.05B | +10.9% |
| ▲ Q1 FY2025 | Feb 13, 2025 | -$0.14 | -$0.08 | +42.9% | $0.05B | $0.05B | +1.8% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.17 | -$0.09 | +47.1% | $0.05B | $0.05B | -3.0% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.82
EPS Est.
-$0.53
EPS Surpr.
-54.7%
Revenue
$0.05B
Q1 FY2026
Feb 11, 2026Beat
EPS Actual
-$0.46
EPS Est.
-$2.18
EPS Surpr.
+78.9%
Revenue
$0.06B
Q4 FY2025
Oct 29, 2025Miss
EPS Actual
-$0.38
EPS Est.
-$0.31
EPS Surpr.
-22.6%
Revenue
$0.06B
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.34
EPS Surpr.
-35.3%
Revenue
$0.05B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$0.55
EPS Surpr.
+9.1%
Revenue
$0.05B
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.14
EPS Surpr.
+42.9%
Revenue
$0.05B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.09
EPS Est.
-$0.17
EPS Surpr.
+47.1%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2027 | $-0.14 | $-0.13 | $-0.12 | 1 |
| Q2 FY2027 | $-0.22 | $-0.21 | $-0.19 | 1 |
| Q1 FY2027 | $-0.37 | $-0.35 | $-0.33 | 1 |
| Q4 FY2026 | $-0.39 | $-0.37 | $-0.35 | 1 |
| Q3 FY2026 | $-0.61 | $-0.52 | $-0.44 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -54.7% | $7.39 | $7.44 | +0.68% |
| ▲ Q1 FY2026 | Feb 11, 2026 | +78.9% | $7.42 | $7.43 | +0.13% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -22.6% | $5.58 | $5.41 | -3.05% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -35.3% | $4.67 | $4.26 | -8.78% |
| ▲ Q2 FY2025 | May 7, 2025 | +9.1% | $4.37 | $4.38 | +0.23% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +42.9% | $4.75 | $4.70 | -1.05% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +47.1% | $4.79 | $4.89 | +2.09% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +61.9% | $5.84 | $5.84 | +0.00% |
Q2 FY2026+0.68%
Report Date
May 6, 2026
EPS Beat/Miss
-54.7%
Price Before
$7.39
Price After
$7.44
Q1 FY2026+0.13%
Report Date
Feb 11, 2026
EPS Beat/Miss
+78.9%
Price Before
$7.42
Price After
$7.43
Q4 FY2025-3.05%
Report Date
Oct 29, 2025
EPS Beat/Miss
-22.6%
Price Before
$5.58
Price After
$5.41
Q3 FY2025-8.78%
Report Date
Jul 31, 2025
EPS Beat/Miss
-35.3%
Price Before
$4.67
Price After
$4.26
Q2 FY2025+0.23%
Report Date
May 7, 2025
EPS Beat/Miss
+9.1%
Price Before
$4.37
Price After
$4.38
Q1 FY2025-1.05%
Report Date
Feb 13, 2025
EPS Beat/Miss
+42.9%
Price Before
$4.75
Price After
$4.70
Q4 FY2024+2.09%
Report Date
Nov 6, 2024
EPS Beat/Miss
+47.1%
Price Before
$4.79
Price After
$4.89
Q3 FY2024+0.00%
Report Date
Jul 31, 2024
EPS Beat/Miss
+61.9%
Price Before
$5.84
Price After
$5.84
Avg Beat Reaction+0.28%
Avg Miss Reaction-3.72%
Beat Rate5 / 8 quarters
Largest Move-8.78% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VNDA ends December
Vanda Pharmaceuticals Inc. (VNDA) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.82 — missing the analyst consensus of $-0.53 by -54.7%. The next VNDA earnings date is expected around September 1, 2026.
Each quarter, investors track VNDA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VNDA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VNDA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VNDA earnings · 5 questionsVanda Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. VNDA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VNDA historically reports after market close (AMC).
VNDA earnings datewhen is VNDA earningsVNDA next earnings datewhen does VNDA report earningsVNDA earnings calendar
▸ Source: FMP · Vanda Pharmaceuticals Inc. SEC filings · US GAAP · Vanda Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026